Bioquell to unveil advanced pathogen eradication technology at annual IPS conference

Antibiotic-resistant pathogens such as CPE and hospital-acquired infections like C.difficile or norovirus seem to be relentlessly lurking around NHS hospitals. Whilst the importance of hand hygiene can’t be stressed enough, the UK’s bio-decontamination specialist will be unveiling the next generation in pathogen eradication technology at the annual IPS conference in Liverpool from 28th to 30th September, stand No. 127.

After years of working closely with the healthcare sector, Bioquell has developed a range of bio-decontamination services based on hydrogen peroxide vapour (HPV) technology, the gold standard in pathogen eradication. Bioquell’s team of experts can respond to any kind of situation from an emergency deployment following an outbreak to after-hours interventions, as well as offer a fully-managed, day-to-day infection control solution.

Along with the flexible bio-decontamination services, Bioquell will present its infection control enclosure, the Bioquell Pod. Tackling the lack of single patient rooms inherent in NHS hospitals, the Pod helps provide patient isolation and segregation to facilitate patient flow and limit the spread of pathogens. Designed individually and tailor-made to fit any bedspace, it doesn’t require ward or unit closure during its simple installation. It can also be decontaminated following patient discharge in under an hour using Bioquell HPV technology.

Sam Burroughes, Bioquell Healthcare Territory Manager (North UK), explains:

IPS 2015 will mark the launch of our new HPV generator, the BQ-50, and a range of services that comes with this great innovation. Its compact size and ease-of-use has opened a whole new world of possibilities to make Bioquell HPV technology even more accessible and flexible to use for hospitals.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Effectiveness of COVID-19 vaccination during Delta variant predominance